Amyloid PET Imaging in Lewy Body Disorders
Open accessThe DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Abstract
Lewy body (LB) disorders, including Parkinson disease (PD), Parkinson disease dementia (PDD), and dementia with Lewy bodies (DLB), are the second most common type of neurodegenerative dementia. Although the pathological hallmarks of LB disorders are Lewy bodies and Lewy neurites, cortical amyloid-beta (Aβ) deposition is also often seen. The relationship between Aβ pathology and dementia in LB disorders is unclear. Recently, positron emission tomography Aβ ligands have been developed that enable in vivo imaging of Aβ. In this paper we review amyloid imaging studies in LB disorders. LB disorders are associated with lower mean cortical Aβ ligand binding compared with Alzheimer disease. In DLB and PDD many subjects have normal levels of cortical Aβ, though a subset show increased Aβ ligand binding. Those with DLB show greater ligand binding than PDD; binding does not appear to be increased in PD without dementia. Cortical Aβ deposition may be a factor in the development of cognitive impairment in some cases of dementia in LB disorders. Amyloid imaging is of limited use in the diagnosis of LB disorders but Aβ deposition may predict the future development of dementia in PD. Reports of correlation between Aβ deposition and symptom profile, severity, and progression have been inconsistent. Some results suggest a synergistic interaction between Aβ and α-synuclein. Interpretation of the current evidence is hampered by differing methodologies across studies and small sample sizes. Large, prospective longitudinal studies are needed to clarify the association of Aβ with symptom development, progression, severity, and treatment response in LB disorders.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Neuropathological stageing of Alzheimer-related changes.
Braak, H., & Braak, E. (1991) · Acta Neuropathologica · doi:10.1007/bf00308809 · Cited by 16,123
Diagnosis and management of dementia with Lewy bodies: Third report of the DLB consortium
McKeith, I. G., Dickson, D. W., Lowe, J., Emre, M., O'Brien, J. T., Feldman, H., Cummings, J., Duda, J. E., Lippa, C., Perry, E. K., et al. (2005) · Neurology · doi:10.1212/01.wnl.0000187889.17253.b1 · Cited by 5,069
Self-citationMcKeith, I. G., Galasko, D., Kosaka, K., Perry, E. K., Dickson, D. W., Hansen, L. A., Salmon, D. P., Lowe, J., Mirra, S. S., Byrne, E. J., et al. (1996) · Neurology · doi:10.1212/wnl.47.5.1113 · Cited by 3,960
Clinical diagnostic criteria for dementia associated with Parkinson’s disease
Emre, M., Aarsland, D., Brown, R., Burn, D. J., Duyckaerts, C., Mizuno, Y., Broe, G. A., Cummings, J., Dickson, D. W., Gauthier, S., et al. (2007) · Movement Disorders · doi:10.1002/mds.21507 · Cited by 3,027
Use of Florbetapir-PET for Imaging β-Amyloid Pathology
Clark, C. M. (2011) · JAMA · doi:10.1001/jama.2010.2008 · Cited by 1,117
Imaging β-amyloid burden in aging and dementia
Rowe, C. C., Ng, S., Ackermann, U., Gong, S. J., Pike, K., Savage, G., Cowie, T. F., Dickinson, K. L., Maruff, P., Darby, D., et al. (2007) · Neurology · doi:10.1212/01.wnl.0000261919.22630.ea · Cited by 1,104
Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease
Ikonomovic, M. D., Klunk, W. E., Abrahamson, E. E., Mathis, C. A., Price, J. C., Tsopelas, N. D., Lopresti, B. J., Ziolko, S., Bi, W., Paljug, W. R., et al. (2008) · Brain · doi:10.1093/brain/awn016 · Cited by 933
Masliah, E., Rockenstein, E., Veinbergs, I., Sagara, Y., Mallory, M., Hashimoto, M., & Mucke, L. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.211412398 · Cited by 607
Clinton, L. K., Blurton-Jones, M., Myczek, K., Trojanowski, J. Q., & LaFerla, F. M. (2010) · The Journal of Neuroscience · doi:10.1523/jneurosci.0490-10.2010 · Cited by 576
Neuropathologic substrates of Parkinson disease dementia
Irwin, D. J., White, M. T., Toledo, J. B., Xie, S. X., Robinson, J. L., Van Deerlin, V., Lee, V. M. ‐., Leverenz, J. B., Montine, T. J., Duda, J. E., et al. (2012) · Annals of Neurology · doi:10.1002/ana.23659 · Cited by 518
Research works printed but not linked: 55
- Stevens, 2002, Islington study of dementia subtypes in the community, Br J Psychiatry, 180, 270, 10.1192/bjp.180.3.270 · DOI · Paper page
- McKeith, 2009, Commentary: DLB and PDD: the same or different? Is there a debate?, Int Psychogeriatr, 21, 220, 10.1017/S1041610208008624 · DOI
- Kovari, 2009, Neuropathology of Lewy body disorders, Brain Res Bull, 80, 203, 10.1016/j.brainresbull.2009.06.018 · DOI
- Merdes, 2003, Influence of Alzheimer pathology on clinical diagnostic accuracy in dementia with Lewy bodies, Neurology, 60, 1586, 10.1212/01.WNL.0000065889.42856.F2 · DOI · Paper page
- Weisman, 2007, In dementia with Lewy bodies, Braak stage determines phenotype, not Lewy body distribution, Neurology, 69, 356, 10.1212/01.wnl.0000266626.64913.0f · DOI · Paper page
- Del Ser, 2001, Clinical and pathologic features of two groups of patients with dementia with Lewy bodies: effect of coexisting Alzheimer-type lesion load, Alzheimer Dis Assoc Disord, 15, 31, 10.1097/00002093-200101000-00005 · DOI · Paper page
- Fujishiro, 2010, Distribution of cerebral amyloid deposition and its relevance to clinical phenotype in Lewy body dementia, Neurosci Lett, 486, 19, 10.1016/j.neulet.2010.09.036 · DOI
- Selikhova, 2009, A clinico-pathological study of subtypes in Parkinson's disease, Brain, 132, 2947, 10.1093/brain/awp234 · DOI · Paper page
- Aarsland, 2004, Are Parkinson's disease with dementia and dementia with Lewy bodies the same entity?, J Geriatr Psychiatry Neurol, 17, 137, 10.1177/0891988704267470 · DOI · Paper page
- Jellinger, 2003, Clinical and neuropathological correlates of Lewy body disease, Acta Neuropathol, 106, 188, 10.1007/s00401-003-0721-2 · DOI
- Pletnikova, 2005, Abeta deposition is associated with enhanced cortical alpha-synuclein lesions in Lewy body diseases, Neurobiol Aging, 26, 1183, 10.1016/j.neurobiolaging.2004.10.006 · DOI · Paper page
- Rowe, 2011, Brain amyloid imaging, J Nucl Med, 52, 1733, 10.2967/jnumed.110.076315 · DOI · Paper page
- Sojkova, 2011, In vivo fibrillar beta-amyloid detected using [11C]PiB positron emission tomography and neuropathologic assessment in older adults, Arch Neurol, 68, 232, 10.1001/archneurol.2010.357 · DOI · Paper page
- Quigley, 2011, PET imaging of brain amyloid in dementia: a review, Int J Geriatr Psychiatry, 26, 991, 10.1002/gps.2640 · DOI · Paper page
- Rosenberg, 2013, Cognition and amyloid load in Alzheimer disease imaged with florbetapir F 18(AV-45) positron emission tomography, Am J Geriatr Psychiatry, 21, 272, 10.1016/j.jagp.2012.11.016 · DOI
- Edison, 2008, Amyloid load in Parkinson's disease dementia and Lewy body dementia measured with [11C]PIB positron emission tomography, J Neurol Neurosurg Psychiatry, 79, 1331, 10.1136/jnnp.2007.127878 · DOI · Paper page
- Gomperts, 2012, Brain amyloid and cognition in Lewy body diseases, Mov Disord, 27, 965, 10.1002/mds.25048 · DOI · Paper page
- Kantarci, 2012, Multimodality imaging characteristics of dementia with Lewy bodies, Neurobiol Aging, 33, 2091, 10.1016/j.neurobiolaging.2011.09.024 · DOI · Paper page
- Foster, 2010, Amyloid imaging of Lewy body-associated disorders, Mov Disord, 25, 2516, 10.1002/mds.23393 · DOI · Paper page
- Villemagne, 2011, Amyloid Imaging with F-18-Florbetaben in Alzheimer Disease and Other Dementias, J Nucl Med, 52, 1210, 10.2967/jnumed.111.089730 · DOI · Paper page
- Claassen, 2011, Amyloid and glucose imaging in dementia with Lewy bodies and multiple systems atrophy, Parkinsonism Relat Disord, 17, 160, 10.1016/j.parkreldis.2010.12.006 · DOI
- Maetzler, 2008, [11C]PIB binding in Parkinson's disease dementia, Neuroimage, 39, 1027, 10.1016/j.neuroimage.2007.09.072 · DOI
- Petrou, 2012, Abeta-amyloid deposition in patients with Parkinson disease at risk for development of dementia, Neurology, 79, 1161, 10.1212/WNL.0b013e3182698d4a · DOI · Paper page
- Maetzler, 2009, Cortical PIB binding in Lewy body disease is associated with Alzheimer-like characteristics, Neurobiol Dis, 34, 107, 10.1016/j.nbd.2008.12.008 · DOI · Paper page
- Shimada H, Shinotoh H, Hirano S, et al: Beta-amyloid in Lewy body disease is related to Alzheimer's disease-like atrophy. Mov Disord 2013; 28:169–175 · DOI · Paper page
- Jokinen, 2010, [(11)C]PIB-, [(18)F]FDG-PET and MRI imaging in patients with Parkinson's disease with and without dementia, Parkinsonism Relat Disord, 16, 666, 10.1016/j.parkreldis.2010.08.021 · DOI
- Johansson, 2008, [(11)C]-PIB imaging in patients with Parkinson's disease: preliminary results, Parkinsonism Relat Disord, 14, 345, 10.1016/j.parkreldis.2007.07.010 · DOI
- Gomperts, 2013, Amyloid is linked to cognitive decline in patients with Parkinson disease without dementia, Neurology, 80, 85, 10.1212/WNL.0b013e31827b1a07 · DOI · Paper page
- Graff-Radford, 2012, Imaging and acetylcholinesterase inhibitor response in dementia with Lewy bodies, Brain, 135, 2470, 10.1093/brain/aws173 · DOI · Paper page
- Sinha, 2012, Biomarkers in dementia with Lewy bodies: a review, Int J Geriatr Psychiatry, 27, 443, 10.1002/gps.2749 · DOI
- Burke, 2011, Assessment of mild dementia with amyloid and dopamine terminal positron emission tomography, Brain, 134, 1647, 10.1093/brain/awr089 · DOI · Paper page
- Bacskai, 2007, Molecular imaging with Pittsburgh Compound B confirmed at autopsy: a case report, Arch Neurol, 64, 431, 10.1001/archneur.64.3.431 · DOI · Paper page
- Burack, 2010, In vivo amyloid imaging in autopsy-confirmed Parkinson disease with dementia, Neurology, 74, 77, 10.1212/WNL.0b013e3181c7da8e · DOI · Paper page
- Kantarci, 2012, Ante mortem amyloid imaging and beta-amyloid pathology in a case with dementia with Lewy bodies, Neurobiol Aging, 33, 878, 10.1016/j.neurobiolaging.2010.08.007 · DOI · Paper page
- Ikonomovic, 2012, Early AD pathology in a C-11 PiB-negative case: a PiB-amyloid imaging, biochemical, and immunohistochemical study, Acta Neuropathol, 123, 433, 10.1007/s00401-012-0943-2 · DOI · Paper page
- Harding, 2001, Cortical Lewy body pathology in the diagnosis of dementia, Acta Neuropathol, 102, 355, 10.1007/s004010100390 · DOI · Paper page
- Jellinger, 2008, Prevalence and impact of vascular and Alzheimer pathologies in Lewy body disease, Acta Neuropathol, 115, 427, 10.1007/s00401-008-0347-5 · DOI · Paper page
- Compta, 2011, Lewy- and Alzheimer-type pathologies in Parkinson's disease dementia: which is more important?, Brain, 134, 1493, 10.1093/brain/awr031 · DOI · Paper page
- Mirra, 1991, The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease, Neurology, 41, 479, 10.1212/WNL.41.4.479 · DOI · Paper page
- Kempster, 2007, Patterns of levodopa response in Parkinson's disease: a clinico-pathological study, Brain, 130, 2123, 10.1093/brain/awm142 · DOI · Paper page
- Jellinger, 2002, Impact of coexistent Alzheimer pathology on the natural history of Parkinson's disease, J Neural Transm, 109, 329, 10.1007/s007020200027 · DOI · Paper page
- Aarsland, 2005, Neuropathology of dementia in Parkinson's disease: a prospective, community-based study, Ann Neurol, 58, 773, 10.1002/ana.20635 · DOI · Paper page
- Lashley, 2008, Cortical alpha-synuclein load is associated with amyloid-beta plaque burden in a subset of Parkinson's disease patients, Acta Neuropathol, 115, 417, 10.1007/s00401-007-0336-0 · DOI · Paper page
- Ballard, 2004, Neuropathological substrates of psychiatric symptoms in prospectively studied patients with autopsy-confirmed dementia with lewy bodies, Am J Psychiatry, 161, 843, 10.1176/appi.ajp.161.5.843 · DOI · Paper page
- Serby, 2003, Cognitive burden and excess Lewy-body pathology in the Lewy-body variant of Alzheimer disease, Am J Geriatr Psychiatry, 11, 371, 10.1176/appi.ajgp.11.3.371 · doi:10.1176/appi.ajgp.11.3.371
- Kraybill, 2005, Cognitive differences in dementia patients with autopsy-verified AD, Lewy body pathology, or both, Neurology, 64, 2069, 10.1212/01.WNL.0000165987.89198.65 · DOI · Paper page
- Mattila, 2000, Alpha-synuclein-immunoreactive cortical Lewy bodies are associated with cognitive impairment in Parkinson's disease, Acta Neuropathol, 100, 285, 10.1007/s004019900168 · DOI · Paper page
- Braak, 2005, Cognitive status correlates with neuropathologic stage in Parkinson disease, Neurology, 64, 1404, 10.1212/01.WNL.0000158422.41380.82 · DOI · Paper page
- Sabbagh, 2009, Parkinson disease with dementia: comparing patients with and without Alzheimer pathology, Alzheimer Dis Assoc Disord, 23, 295, 10.1097/WAD.0b013e31819c5ef4 · DOI · Paper page
- Moghbel, 2012, Amyloid-beta imaging with PET in Alzheimer's disease: is it feasible with current radiotracers and technologies?, Eur J Nucl Med Mol Imaging, 39, 202, 10.1007/s00259-011-1960-4 · DOI
- Villemagne, 2012, A beta imaging: feasible, pertinent, and vital to progress in Alzheimer's disease, Eur J Nucl Med Mol Imaging, 39, 209, 10.1007/s00259-011-2045-0 · DOI
- Svedberg, 2009, [(11)C]PIB-amyloid binding and levels of Abeta40 and Abeta42 in postmortem brain tissue from Alzheimer patients, Neurochem Int, 54, 347, 10.1016/j.neuint.2008.12.016 · DOI
- Herholz, 2011, Clinical amyloid imaging in Alzheimer's disease, Lancet Neurol, 10, 667, 10.1016/S1474-4422(11)70123-5 · DOI · Paper page
- Fujishiro, 2008, Validation of the neuropathologic criteria of the third consortium for dementia with Lewy bodies for prospectively diagnosed cases, J Neuropathol Exp Neurol, 67, 649, 10.1097/NEN.0b013e31817d7a1d · DOI · Paper page
- Burton, 2009, Medial temporal lobe atrophy on MRI differentiates Alzheimer's disease from dementia with Lewy bodies and vascular cognitive impairment: a prospective study with pathological verification of diagnosis, Brain, 132, 195, 10.1093/brain/awn298 · DOI · Paper page
Cited by
Walker, Z., Possin, K. L., Boeve, B. F., & Aarsland, D. (2015) · The Lancet · doi:10.1016/s0140-6736(15)00462-6 · Cited by 592
Borghammer, P. (2021) · Journal of Parkinson's Disease · doi:10.3233/jpd-202481 · Cited by 259
Evaluation of early-phase [18F]-florbetaben PET acquisition in clinical routine cases
Daerr, S., Brendel, M., Zach, C., Mille, E., Schilling, D., Zacherl, M. J., Bürger, K., Danek, A., Pogarell, O., Schildan, A., et al. (2017) · NeuroImage: Clinical · doi:10.1016/j.nicl.2016.10.005 · Cited by 124
Neuroimaging characteristics of dementia with Lewy bodies
Mak, E., Su, L., Williams, G. B., & O’Brien, J. T. (2014) · Alzheimer's Research & Therapy · doi:10.1186/alzrt248 · Cited by 120
“The variation in patient population, sample size and subtle differences in imaging analysis methodology may account for such mixed effects in comparing GM reduction between the DLB and PDD groups; for example, VBM has been shown to be highly sensitive to co-registration and normalisation errors.”
BackgroundResultInfluentialSelf-citationStylianou, M., Murphy, N., Peraza, L. R., Graziadio, S., Cromarty, R., Killen, A., O' Brien, J. T., Thomas, A. J., LeBeau, F. E. N., & Taylor, J.-P. (2018) · Clinical Neurophysiology · doi:10.1016/j.clinph.2018.03.013 · Cited by 79
Self-citation
Metadata
- Authors
- Donaghy, P., Thomas, A. J., & O'Brien, J. T.
- Venue
- The American Journal of Geriatric Psychiatry
- Publisher
- Elsevier BV
- Published
- 2015-01
- Volume
- 23
- Issue
- 1
- Pages
- 23-37
- ISSN
- 1064-7481 (ISSN-L)
- OpenAlex
- W2092013637
- Cited by
- 117
- References
- 19
- FWCI
- 6.80
- Type
- journal article
- Language
- en
- Open access
- green
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- Funders
- National Institute for Health Research
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Amyloid PET Imaging in Lewy Body Disorders. https://app.cochat.ai/papers/10.1016/j.jagp.2013.03.001
- The paper
- Donaghy, P., Thomas, A. J., & O'Brien, J. T. (2015). Amyloid PET Imaging in Lewy Body Disorders. The American Journal of Geriatric Psychiatry. https://doi.org/10.1016/j.jagp.2013.03.001
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.